History of GLP-1 Medications: From Discovery to 2026
Disclaimer: betterresultsbook.com contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. betterresultsbook.com makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. betterresultsbook.com makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.
GLP-1 medications have transformed modern medicine, evolving from an obscure gut hormone discovered in the 1980s to today’s blockbuster drugs like Ozempic, Wegovy, and Mounjaro. The first GLP-1 medication, Byetta (exenatide), received FDA approval in April 2005 for type 2 diabetes, and remarkably, its key ingredient came from the saliva of a Gila monster.
In 2026, GLP-1 receptor agonists represent one of the most significant pharmaceutical breakthroughs of our generation. These medications have helped millions manage diabetes and obesity, with some experts projecting that 9% of the US population could be using them by 2030.
I’ve spent considerable time researching the fascinating journey of GLP-1 medications from laboratory curiosity to life-changing therapeutics. What struck me most was how this story interweaves scientific persistence, serendipitous discoveries, and decades of incremental progress.
In this comprehensive guide, you’ll discover the key milestones, the scientists who made them possible, and what the future holds for these remarkable medications.
The Discovery Era (1960s-1980s)
The history of GLP-1 medications begins with a scientific puzzle that baffled researchers for decades: why does sugar taken by mouth trigger a stronger insulin response than sugar injected directly into the bloodstream?
The Incretin Effect: A Mysterious Discovery
In the 1960s and 1970s, scientists observed something unexpected. When patients consumed glucose orally, their bodies released significantly more insulin compared to when the same amount of glucose was administered intravenously.
This phenomenon became known as the “incretin effect.” It suggested that something in the gut was signaling the pancreas to ramp up insulin production. The hunt was on to identify these mysterious gut hormones.
The first breakthrough came in the 1970s when researchers isolated GIP (glucose-dependent insulinotropic polypeptide) from porcine gastric extracts. This confirmed that incretin hormones existed and could influence insulin secretion.
However, GIP alone couldn’t explain the full incretin effect. Scientists suspected another hormone was involved.
Identifying the GLP-1 Hormone
The second piece of the puzzle fell into place between 1983 and 1984. Following the cloning of glucagon cDNAs and genes, researchers identified a new peptide sequence within the proglucagon gene.
This peptide, produced by L-cells in the small intestine, was named glucagon-like peptide-1, or GLP-1. Unlike glucagon, which raises blood sugar, GLP-1 had the opposite effect.
By the late 1980s, researchers had mapped out GLP-1’s remarkable functions. The hormone stimulates glucose-dependent insulin secretion, inhibits glucagon release, and slows gastric emptying. These properties made it an attractive target for diabetes treatment.
There was just one problem: native GLP-1 is rapidly destroyed by an enzyme called DPP-4 (dipeptidyl peptidase-4). Its half-life in the human body is less than two minutes, making it impractical as a medication.
Key Discovery: GLP-1 was identified in 1983-1984 as a fragment of proglucagon produced by intestinal L-cells. Research by scientists including Daniel J. Drucker helped characterize its functions.
The Gila Monster Connection: Nature’s Unexpected Gift
The breakthrough that would eventually lead to the first GLP-1 medication came from an unlikely source: a venomous lizard native to the American Southwest.
In 1992, endocrinologist John Eng was working at the Veterans Administration Medical Center when he made a discovery that would change the trajectory of diabetes treatment. Eng was studying peptides in Gila monster saliva, searching for compounds that might have therapeutic value.
What he found was extraordinary. Gila monster saliva contained a peptide called exendin-4 that closely resembled human GLP-1 but with one crucial difference: it was resistant to breakdown by the DPP-4 enzyme.
The Gila monster had evolved this stable version of an incretin-like hormone because it only eats a few large meals per year. The peptide helps regulate the massive swings in blood sugar that occur after these infrequent feedings.
Eng recognized the therapeutic potential immediately. Here was a natural compound that mimicked GLP-1’s beneficial effects but could actually survive long enough in the human body to be useful as a drug.
“The Gila monster discovery was one of those serendipitous moments in science where studying an unusual organism revealed a solution to a human health problem.”
– Based on accounts of John Eng’s discovery
The journey from discovery to FDA approval would take another 13 years, but the foundation had been laid. Synthetic versions of exendin-4 would become exenatide, marketed under the brand name Byetta, the world’s first GLP-1 receptor agonist.
First FDA Approvals (2005-2012)
The era of GLP-1 medications as approved therapies began on April 28, 2005, when the FDA approved Byetta (exenatide) for the treatment of type 2 diabetes.
Byetta: The Pioneer (2005)
Byetta proved that GLP-1 receptor agonists could effectively lower blood sugar in diabetes patients. The medication required twice-daily injections, given before the two largest meals of the day.
While the injection frequency was a drawback, Byetta demonstrated something important: patients also tended to lose weight while taking it. This “side effect” would later prove to be one of the most significant aspects of GLP-1 medications.
Developed by Amylin Pharmaceuticals and later acquired by AstraZeneca, Byetta opened the door for an entirely new class of diabetes drugs.
Victoza: The Daily Dose (2010)
On January 25, 2010, the FDA approved Victoza (liraglutide), developed by Novo Nordisk. This represented the next evolution in GLP-1 therapy.
Victoza used a clever molecular modification. Scientists attached a fatty acid chain to the GLP-1 molecule, allowing it to bind to albumin in the blood. This extended its duration of action, enabling once-daily dosing instead of twice daily.
The convenience improvement was significant. Patients now needed only one injection per day, at any time, regardless of meals.
Bydureon: The Weekly Option (2012)
Another major advancement came on January 27, 2012, with the FDA approval of Bydureon (extended-release exenatide). Using biodegradable microsphere technology, Bydureon extended the release of exenatide over an entire week.
For the first time, patients could take a GLP-1 medication once weekly. This dramatic improvement in convenience would become the standard for future GLP-1 drugs.
| Drug | FDA Approval | Dosing | Key Advancement |
|---|---|---|---|
| Byetta | April 2005 | Twice daily | First GLP-1 medication |
| Victoza | January 2010 | Once daily | Albumin binding for longer action |
| Bydureon | January 2012 | Once weekly | First weekly GLP-1 option |
The Weight Loss Revolution (2014-2017)
The period from 2014 to 2017 marked a paradigm shift. GLP-1 medications evolved from diabetes treatments to breakthrough obesity therapies, while also demonstrating cardiovascular benefits that surprised even researchers.
Saxenda: First for Obesity (2014)
On December 23, 2014, the FDA approved Saxenda (liraglutide 3.0mg), marking the first time a GLP-1 medication was approved specifically for chronic weight management.
Saxenda was essentially a higher dose of Victoza. While Victoza used liraglutide at doses up to 1.8mg for diabetes, Saxenda used 3.0mg specifically targeting obesity. This approval legitimized what doctors had observed for years: GLP-1 medications could be powerful tools for weight loss.
The approval opened an entirely new market and set the stage for the weight loss revolution that would follow.
Trulicity: Simplified Weekly Dosing (2014)
Also in 2014, Eli Lilly received FDA approval for Trulicity (dulaglutide). This once-weekly GLP-1 agonist came in a prefilled, ready-to-use pen that required no mixing or complicated preparation.
Trulicity’s simplicity made it one of the most popular GLP-1 medications for diabetes management.
Cardiovascular Benefits Discovered (2016)
In 2016, the LEADER trial revealed something remarkable: liraglutide reduced major cardiovascular events by 31% and all-cause mortality by 26% in type 2 diabetes patients with kidney disease.
This finding transformed how doctors viewed GLP-1 medications. They weren’t just glucose-lowering drugs; they offered protection against heart attacks, strokes, and death. This cardiovascular benefit would become a key selling point for the entire class.
Ozempic: The Cultural Phenomenon (2017)
On December 15, 2017, the FDA approved Ozempic (semaglutide), and the landscape of GLP-1 medications would never be the same.
Semaglutide represented an advancement over previous GLP-1 agonists. Clinical trials showed impressive weight loss in addition to blood sugar control. The once-weekly injection was convenient, and its efficacy caught the attention of both patients and physicians.
While approved for type 2 diabetes, Ozempic would eventually become a household name, sparking widespread media coverage and what some called the “Ozempic craze.”
Milestone: The LEADER trial in 2016 established that GLP-1 medications offer cardiovascular protection beyond glucose control, fundamentally changing how these drugs are prescribed.
The Modern Era (2019-Present)
The modern era of GLP-1 medications has been marked by breakthrough innovations, unprecedented demand, and the emergence of dual-agonist therapies that have redefined what’s possible in obesity treatment.
Rybelsus: The First Pill (2019)
In September 2019, the FDA approved Rybelsus (oral semaglutide), the first GLP-1 medication in pill form. This was a significant technical achievement.
Peptide drugs like semaglutide are typically destroyed by stomach acid. Novo Nordisk solved this problem by using SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that protects the drug and facilitates its absorption.
Rybelsus must be taken on an empty stomach with no more than 4 ounces of water, and patients must wait 30 minutes before eating or taking other medications. Despite these restrictions, it offered an alternative for patients reluctant to inject.
Wegovy: The Weight Loss Game-Changer (2021)
June 4, 2021, marked a watershed moment in obesity treatment. The FDA approved Wegovy (semaglutide 2.4mg) for chronic weight management.
Clinical trials had shown that Wegovy produced an average weight loss of approximately 15% of body weight, roughly doubling the efficacy of previous weight loss medications. For a 200-pound person, this translated to losing about 30 pounds.
Demand for Wegovy quickly outstripped supply, leading to widespread shortages that continue to affect patients today.
Mounjaro: The Dual Agonist (2022)
On May 13, 2022, the FDA approved Mounjaro (tirzepatide), representing a new class of medications: dual GLP-1/GIP receptor agonists.
By activating both the GLP-1 and GIP receptors simultaneously, tirzepatide achieved even greater efficacy. Clinical trials showed weight loss of up to 22.5%, approaching what’s typically seen only with bariatric surgery.
Developed by Eli Lilly, Mounjaro was initially approved for type 2 diabetes, but its remarkable weight loss effects were immediately apparent.
Zepbound: Dual Agonist for Obesity (2023)
On November 8, 2023, tirzepatide received FDA approval for chronic weight management under the brand name Zepbound. It became the most effective FDA-approved weight loss medication available.
With both Mounjaro and Zepbound, Eli Lilly had created a dual-agonist platform that set new benchmarks for efficacy.
The Shortage Crisis
The success of GLP-1 medications created an unexpected challenge. Between 2023 and 2026, skyrocketing demand led to widespread shortages. The FDA placed several GLP-1 medications on its drug shortage list.
These shortages allowed compounding pharmacies to legally prepare patient-specific versions of the medications under FDA guidelines. However, it’s important to note that compounded medications are not FDA-approved and may not have the same safety and efficacy profiles as brand-name products.
Note: Compounded medications are not FDA-approved. The FDA only permits compounding of certain drugs when they appear on the official drug shortage list.
Complete FDA Approval Timeline
The following table provides a comprehensive overview of all GLP-1 and related medications approved by the FDA through 2026.
| Year | Brand Name | Generic Name | Indication | Manufacturer | Dosing |
|---|---|---|---|---|---|
| 2005 | Byetta | Exenatide | Type 2 Diabetes | AstraZeneca | Twice daily |
| 2010 | Victoza | Liraglutide | Type 2 Diabetes | Novo Nordisk | Once daily |
| 2012 | Bydureon | Exenatide ER | Type 2 Diabetes | AstraZeneca | Once weekly |
| 2014 | Tanzeum* | Albiglutide | Type 2 Diabetes | GSK | Once weekly |
| 2014 | Trulicity | Dulaglutide | Type 2 Diabetes | Eli Lilly | Once weekly |
| 2014 | Saxenda | Liraglutide 3.0mg | Weight Loss | Novo Nordisk | Once daily |
| 2017 | Ozempic | Semaglutide | Type 2 Diabetes | Novo Nordisk | Once weekly |
| 2017 | Bydureon BCise | Exenatide ER | Type 2 Diabetes | AstraZeneca | Once weekly |
| 2019 | Rybelsus | Oral Semaglutide | Type 2 Diabetes | Novo Nordisk | Once daily (oral) |
| 2020 | Adlyxin | Lixisenatide | Type 2 Diabetes | Sanofi | Once daily |
| 2021 | Wegovy | Semaglutide 2.4mg | Weight Loss | Novo Nordisk | Once weekly |
| 2022 | Mounjaro | Tirzepatide | Type 2 Diabetes | Eli Lilly | Once weekly |
| 2023 | Zepbound | Tirzepatide | Weight Loss | Eli Lilly | Once weekly |
*Tanzeum was discontinued from the market.
The Scientists Behind the Revolution
The development of GLP-1 medications wouldn’t have been possible without the dedication of researchers who spent decades unraveling the mysteries of incretin hormones.
Daniel J. Drucker, MD
Daniel Drucker, based at Mt. Sinai Hospital and the University of Toronto, is widely regarded as one of the pioneers of GLP-1 research. His work has been instrumental in characterizing the glucagon-like peptides and understanding their physiological roles.
Drucker’s research helped establish the foundation for GLP-1 as a therapeutic target. His publications have been cited thousands of times, and his work continues to guide the development of new incretin-based therapies.
John Eng, MD
John Eng’s discovery of exendin-4 in Gila monster saliva in 1992 was the breakthrough that made the first GLP-1 medication possible. Working at the Veterans Administration Medical Center, Eng identified the DPP-4-resistant peptide that would become exenatide (Byetta).
Eng’s discovery demonstrates how studying unusual organisms can yield unexpected medical breakthroughs. His work transformed a compound from lizard saliva into a treatment used by millions.
Michael Nauck, MD
In 1993, Michael Nauck and colleagues made a critical observation: GLP-1’s ability to stimulate insulin secretion remained relatively intact in people with type 2 diabetes, unlike GIP.
This finding was crucial because it meant GLP-1-based drugs could actually work in the patients who needed them most. It shifted research focus toward GLP-1 as the preferred target for diabetes drug development.
The Future of GLP-1 Medications
The GLP-1 story is far from over. Researchers and pharmaceutical companies are working on next-generation therapies that could make today’s medications look primitive by comparison.
Triple Agonists
The most exciting development may be triple agonist drugs that activate GLP-1, GIP, and glucagon receptors simultaneously. By combining appetite suppression, improved blood sugar control, and increased calorie burning, these medications could potentially match bariatric surgery results without surgery.
Several triple agonists are currently in clinical trials, with results expected in the coming years.
Small Molecule Oral GLP-1 Agonists
While Rybelsus proved oral GLP-1 delivery was possible, it required careful dosing conditions. New small molecule GLP-1 agonists like orforglipron are in late-stage clinical development.
Unlike peptide-based drugs, small molecule agonists could be taken more conveniently and may be less expensive to manufacture, potentially improving global access.
Expanded Indications
Researchers are studying GLP-1 medications for conditions beyond diabetes and obesity. Active clinical trials are investigating their potential for:
- Heart failure (specifically HFpEF)
- Diabetic kidney disease
- Peripheral artery disease
- NASH/metabolic liver disease
- Parkinson’s disease
- Alzheimer’s disease
The neuroprotective properties of GLP-1 agonists have generated particular interest, with early research suggesting potential benefits for neurodegenerative conditions.
Market Projections
Industry analysts project that approximately 9% of the US population could be using GLP-1 medications by 2030. This represents massive growth from current adoption rates and would make GLP-1 agonists among the most widely prescribed drug classes in history.
Frequently Asked Questions
What is the history of GLP-1 agonist drugs?
GLP-1 agonist drugs have a history spanning over 40 years. The GLP-1 hormone was identified in 1983-1984. In 1992, John Eng discovered exendin-4 in Gila monster saliva, which led to the first GLP-1 drug. Byetta (exenatide) became the first FDA-approved GLP-1 medication in April 2005. Since then, numerous GLP-1 drugs have been approved, including Ozempic (2017), Wegovy (2021), and Mounjaro (2022).
How was the GLP-1 agonist discovered?
GLP-1 agonist drugs were discovered through research on Gila monster saliva. In 1992, endocrinologist John Eng found that Gila monster saliva contained a peptide called exendin-4 that mimicked human GLP-1 but was resistant to breakdown by the DPP-4 enzyme. This natural compound could survive long enough in the body to be therapeutically useful, leading to the development of exenatide (Byetta), the first GLP-1 medication.
When was the GLP-1 hormone discovered?
The GLP-1 hormone was discovered between 1983 and 1984 following the cloning of glucagon genes. Researchers identified GLP-1 as a fragment of proglucagon produced by L-cells in the small intestine. By the late 1980s, scientists had characterized its functions: stimulating insulin secretion, inhibiting glucagon release, and slowing gastric emptying.
How long have GLP-1 drugs been on the market?
GLP-1 drugs have been on the market since 2005. Byetta (exenatide) was the first GLP-1 medication to receive FDA approval on April 28, 2005. This means GLP-1 medications have been available for approximately 20 years as of 2025. During this time, the class has expanded significantly to include once-daily, once-weekly, and oral formulations.
When was Ozempic approved by the FDA?
Ozempic (semaglutide) was approved by the FDA on December 15, 2017, for the treatment of type 2 diabetes. It is a once-weekly injectable GLP-1 receptor agonist manufactured by Novo Nordisk. Ozempic became widely known for its weight loss effects, leading to its reformulation as Wegovy, which was approved for chronic weight management in June 2021.
What was the first GLP-1 medication?
The first GLP-1 medication was Byetta (exenatide), approved by the FDA on April 28, 2005. It was developed from exendin-4, a compound discovered in Gila monster saliva. Byetta required twice-daily injections and was approved for the treatment of type 2 diabetes. It proved that GLP-1 receptor agonists could effectively lower blood sugar and laid the foundation for all subsequent GLP-1 medications.
Looking Back, Moving Forward
The history of GLP-1 medications is a testament to scientific curiosity, persistence, and the unexpected places where medical breakthroughs can be found. From the discovery of the incretin effect in the 1960s to the Gila monster’s contribution in the 1990s, from the first FDA approval in 2005 to today’s dual-agonist therapies, this class of medications has transformed how we treat diabetes and obesity.
In 2026, GLP-1 medications stand at the forefront of metabolic medicine. With triple agonists in development, expanded indications being studied, and oral formulations improving accessibility, the next chapter of this story promises to be even more remarkable than what came before.
For anyone considering GLP-1 medications, understanding their history provides context for their current role in medicine. These aren’t experimental drugs; they represent four decades of research and two decades of clinical use.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication. GLP-1 medications require a prescription and may not be appropriate for everyone. Individual results may vary.
FDA Disclaimer: Compounded medications are not FDA-approved and may not be available in all states. Only use medications obtained through licensed healthcare providers and pharmacies.
